Business Context and Reporting Period
This Form 8-K, dated September 12, 2025, reports the completion of a strategic acquisition and corporate restructuring by Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc.). The Company, a Delaware corporation headquartered in Kuala Lumpur, Malaysia, has transitioned into a diversified entity operating in both the biopharmaceutical and fire safety equipment sectors.
Key Financial Metrics and Transaction Details
The filing details a share exchange transaction rather than a cash acquisition. Key financial and structural metrics include:
- Acquisition Consideration: The Company issued 699,158 shares of common stock (par value $0.001) to Fitters Diversified Berhad in exchange for 100% of FITTERS Sdn. Bhd. ("Fitters").
- Target Profile: Fitters is a Malaysia-based supplier of protective and fire safety equipment with over 40 years of market presence.
- Financial Statements: Unaudited financial statements for Fitters for the three months ended June 30, 2025, and 2024, as well as pro forma combined financial information for the Company and Fitters, are included as Exhibits 99.2 and 99.3. Specific revenue, profit, or cash flow figures are not stated in the summary text of this filing.
- Debt and Liquidity: The filing text does not provide specific values for the Company's or Fitters' debt levels or liquidity positions.
Material Changes Versus Prior Period
The following material changes were effected on September 12, 2025:
- Corporate Name Change: The Company changed its name from "Cyclacel Pharmaceuticals, Inc." to "Bio Green Med Solution, Inc."
- Trading Symbols: Common stock now trades under the symbol "BGMS" and 6% convertible preferred stock under "BGMSP" on The Nasdaq Capital Market.
- Business Diversification: The Company expanded from a legacy focus on pharmaceutical R&D to include the fire protection industry through the integration of Fitters.
- Governance Changes: Stockholders approved amendments to the Certificate of Incorporation to permit actions by written consent and opt out of Section 203 of the Delaware General Corporation Law (DGCL).
- Leadership: Datuk Dr. Doris Wong Sing Ee, CEO of the Company, was appointed as a director of Fitters.
Guidance, Outlook, and Risks
Management Commentary and Outlook: Management states the Company is now a diversified entity focused on advancing opportunities across biopharmaceutical and fire protection sectors to drive long-term value creation. The integration of Fitters is intended to leverage its reputation for reliability and regulatory compliance in Malaysia's fire safety market.
Risks and Contingencies: The filing references the definitive proxy statement/prospectus (Form S-4) for a complete description of the Exchange Agreement and associated risks. No specific new risks or contingencies are detailed in the text of this 8-K beyond the standard incorporation by reference.
Investor Verification Checklist
- Review the Unaudited Pro Forma Financial Statements (Exhibit 99.3) to assess the combined financial impact of the acquisition on revenue and earnings.
- Examine the Unaudited Financial Statements of Fitters (Exhibit 99.2) to verify the target's standalone financial health and growth trends.
- Consult the Definitive Proxy Statement/Prospectus (Form S-4) filed on July 25, 2025, for the full terms of the Exchange Agreement and risk factors.
- Verify the Trademark License Agreement (Exhibit 10.1) to understand the intellectual property rights retained by Fitters Parent versus those transferred to the Company.
- Monitor the stock trading volume and price under the new symbols (BGMS, BGMSP) following the September 12, 2025, listing.